This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: IntelliCyt Corporation
New iQue Screener Increases Power and Scope of Phenotypic Screening Experiments
Albuquerque, NM, (PRWEB) January 12, 2013
IntelliCyt Corporation, a provider of assay screening solutions for phenotypic drug discovery, antibody discovery and in vitro toxicity testing, today announced the introduction of their new iQue™ Screener. The new system is the latest addition to IntelliCyt’s platform of instrumentation, application-specific reagents, integrated multi-user analysis and informatics tools. The iQue Screener will be unveiled tomorrow at the Society for Laboratory Automation and Screening (SLAS) 2nd Annual Conference in Orlando, Florida.
“The iQue Screener is our next generation system, integrating IntelliCyt’s technology into an instrument that is ideal for the screening environment. Researchers can now evaluate compound effects on non-adherent cell lines, primary immune system cells and molecular interactions using cell or bead-based screening assays”, commented Terry Dunlay, CEO at IntelliCyt. “Laboratories will see a drastic reduction in time to final results and be able to generate higher quality and more reproducible data. Our early access customers have been very happy with the ease of use, workflow support and powerful data analysis capabilities the system provides.”
IntelliCyt’s screening systems for cell and bead-based assays are the first high-throughput, high-content bench top analyzers designed for rapid screening of cells and beads in suspension. Unlike other screening technologies that provide data on a per well basis, IntelliCyt’s technology provides information-rich data on a cell by cell basis in 96- and 384-well microplates. Micro-volume sample delivery combined with rapid sample processing and highly sensitive multiplexing capabilities let researchers in many fields screen large libraries at unprecedented speed and also drastically reduce costs.
About IntelliCyt Corporation
IntelliCyt Corporation develops innovative, high-throughput, high-content cell and bead-based screening solutions for use in phenotypic drug discovery, antibody discovery and in vitro toxicity testing. IntelliCyt’s proprietary technologies, instrumentation, assays and software products address the pervasive need to provide turnkey solutions that increase productivity in pharmaceutical, biotechnology, and life science research. For more information, please visit http://www.intellicyt.com.
Michael Sjaastad, Director of Business Development
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/1/prweb10314119.htm